Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 5/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 3/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871009 | 0.91 | ALOX5AP (0.35) | GPR52ALOX5APFEN1MAPK3MEN1 | |
| SCHEMBL869975 | 0.90 | ALOX5AP (0.35) | GPR52ALOX5APFEN1MEN1CACNA1B | |
| SCHEMBL10072350 | 0.90 | ALOX5AP (0.35) | GPR52ALOX5APFEN1MAPK3MEN1 | |
| SCHEMBL871473 | 0.89 | P2RX7 (0.32) | RPS6KB1P2RX7CXCR5 | |
| SCHEMBL871102 | 0.87 | NTRK1 (0.33) | GPR52ALOX5APFEN1MAPK3MEN1 | |
| SCHEMBL876189 | 0.87 | CA1 (0.33) | RPS6KB1CXCR5 | |
| SCHEMBL871002 | 0.86 | KMT2A (0.36) | ALOX5APFEN1MEN1CACNA1BAPBA1 | |
| SCHEMBL870579 | 0.86 | MEN1 (0.36) | GPR52ALOX5APFEN1MEN1CACNA1B | |
| SCHEMBL869750 | 0.85 | GPR52 (0.35) | GPR52ALOX5APFEN1MEN1CACNA1B | |
| SCHEMBL871765 | 0.85 | GPR52 (0.37) | GPR52ALOX5APFEN1MEN1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619189-B1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012038851-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | CYP1A2, CYP3A7, CYP2E1 | GPR52 1054/4885ALOX5AP 2971/4885FEN1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.